Neurocrine Biosciences INC (NBIX) Stock Rose While Fosun International LTD Has Upped Holding by $3.32 Million

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) LogoInvestors sentiment increased to 1.44 in Q1 2019. Its up 0.45, from 0.99 in 2018Q4. It increased, as 37 investors sold NBIX shares while 71 reduced holdings. 45 funds opened positions while 110 raised stakes. 101.77 million shares or 17.27% more from 86.79 million shares in 2018Q4 were reported. California State Teachers Retirement Sys owns 142,451 shares. Aperio Group Ltd Com owns 28,100 shares. Moreover, Pointstate Capital Lp has 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). California Public Employees Retirement Sys has 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 124,100 shares. Kepos Capital Lp has invested 0.36% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Brinker Inc invested in 0.03% or 10,352 shares. Van Eck Associates, New York-based fund reported 113,766 shares. Marshall Wace Limited Liability Partnership reported 0.31% stake. Quantbot Lp has invested 0.03% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). State Common Retirement Fund has 0.03% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Opus Point Prns Mngmt Lc stated it has 2,807 shares or 0.33% of all its holdings. 84,169 were accumulated by Jacobs Levy Equity Mngmt Inc. 954,670 are owned by Natl Bank Of Mellon. 3.37 million were reported by Bb Biotech Ag. Qs Lc stated it has 0% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Fosun International Ltd increased its stake in Neurocrine Biosciences Inc (NBIX) by 62.58% based on its latest 2019Q1 regulatory filing with the SEC. Fosun International Ltd bought 39,000 shares as the company’s stock rose 29.28% . The institutional investor held 101,323 shares of the health care company at the end of 2019Q1, valued at $8.67M, up from 62,323 at the end of the previous reported quarter. Fosun International Ltd who had been investing in Neurocrine Biosciences Inc for a number of months, seems to be bullish on the $8.69 billion market cap company. The stock increased 0.53% or $0.5 during the last trading session, reaching $94.88. About 483,284 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has declined 2.64% since August 15, 2018 and is downtrending. It has underperformed by 2.64% the S&P500.

Fosun International Ltd, which manages about $1.57 billion US Long portfolio, decreased its stake in Merck & Co Inc (NYSE:MRK) by 65,650 shares to 22,230 shares, valued at $1.84 million in 2019Q1, according to the filing. It also reduced its holding in Colony Cap Inc New by 7.04M shares in the quarter, leaving it with 9.64M shares, and cut its stake in Makemytrip Limited Mauritius (NASDAQ:MMYT).

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Nasdaq.com which released: “Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Top Estimates – Nasdaq” on July 29, 2019, also Nasdaq.com with their article: “Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil – Nasdaq” published on August 09, 2019, Nasdaq.com published: “Notable Tuesday Option Activity: JOE, NBIX, WWE – Nasdaq” on July 30, 2019. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Nasdaq.com and their article: “Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? – Nasdaq” published on July 22, 2019 as well as Nasdaq.com‘s news article titled: “Oversold Conditions For Neurocrine Biosciences (NBIX) – Nasdaq” with publication date: November 14, 2018.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 8 analysts covering Neurocrine (NASDAQ:NBIX), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Neurocrine has $127 highest and $87 lowest target. $108.25’s average target is 14.09% above currents $94.88 stock price. Neurocrine had 15 analyst reports since March 12, 2019 according to SRatingsIntel. The stock has “Buy” rating by Cowen & Co on Wednesday, March 13. The firm has “Hold” rating by Leerink Swann given on Tuesday, March 12. As per Wednesday, March 13, the company rating was maintained by H.C. Wainwright. The rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, March 12. The stock has “Overweight” rating by Piper Jaffray on Tuesday, July 30. The company was maintained on Tuesday, July 30 by Credit Suisse. The rating was upgraded by JP Morgan on Monday, April 22 to “Overweight”.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.